Bierer D E, Fort D M, Mendez C D, Luo J, Imbach P A, Dubenko L G, Jolad S D, Gerber R E, Litvak J, Lu Q, Zhang P, Reed M J, Waldeck N, Bruening R C, Noamesi B K, Hector R F, Carlson T J, King S R
Shaman Pharmaceuticals, Inc., South San Francisco, California 94080, USA.
J Med Chem. 1998 Mar 12;41(6):894-901. doi: 10.1021/jm9704816.
Using an ethnobotanical approach in combination with in vivo-guided fractionation as a means for lead discovery, cryptolepine was isolated as an antihyperglycemic component of Cryptolepis sanguinolenta. Two syntheses of cryptolepine, including an unambiguous synthesis, are reported. The hydroiodide, hydrochloride, and hydrotrifluoromethanesulfonate (hydrotriflate) salts of cryptolepine were synthesized, and a comparison of their spectral properties and their in vitro activities in a 3T3-L1 glucose transport assay is made. Cryptolepine and its salt forms lower blood glucose in rodent models of type II diabetes. While a number of bioactivities have been reported for cryptolepine, this is the first report that cryptolepine possesses antihyperglycemic properties.
采用民族植物学方法并结合体内导向分级分离作为先导化合物发现手段,隐丹参酮被分离出来作为红根草的一种降血糖成分。报道了隐丹参酮的两种合成方法,包括一种明确的合成方法。合成了隐丹参酮的氢碘酸盐、盐酸盐和三氟甲磺酸氢盐(氢三氟甲磺酸盐),并对它们在3T3-L1葡萄糖转运试验中的光谱性质和体外活性进行了比较。隐丹参酮及其盐形式可降低II型糖尿病啮齿动物模型的血糖。虽然已经报道了隐丹参酮的多种生物活性,但这是首次报道隐丹参酮具有降血糖特性。